<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765804</url>
  </required_header>
  <id_info>
    <org_study_id>EGP-437-002</org_study_id>
    <nct_id>NCT00765804</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye</brief_title>
  <official_title>Evaluation of Dexamethasone Phosphate Delivered by Ocular Iontophoresis for Treatment of Dry Eye in the Controlled Adverse Environment Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyegate Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyegate Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of iontophoretic delivery of
      dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in
      patients with dry eye.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to assess the safety and efficacy of Ocular Iontophoresis with
      Dexamethasone Phosphate 40 mg/mL 7.5 mA-min at 2.5 mA and Ocular Iontophoresis with
      Dexamethasone Phosphate 40 mg/mL 10.5 mA-min at 3.5 mA compared to placebo for the treatment
      of the signs and symptoms of dry eye.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sign: Corneal fluorescein staining after CAE exposure at Visit 5</measure>
    <time_frame>Visit 5 (Day 7 ± 2 Days)</time_frame>
    <description>Corneal fluorescein staining after CAE exposure at Visit 5 as measured by the ORA scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom: Ocular discomfort during CAE exposure at Visit 5</measure>
    <time_frame>Visit 5 (Day 7 ± 2 Days)</time_frame>
    <description>Symptom: Ocular discomfort during CAE exposure at Visit 5 as measured by ORA scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sign: Fluorescein staining at each visit over 3 weeks</measure>
    <time_frame>7 visits / 3 weeks</time_frame>
    <description>Fluorescein staining (each region) as measured by the ORA and NEI Scales at each of 7 visits over 3 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom: Ocular discomfort pre and post CAE</measure>
    <time_frame>Visit 1 (Day -7 ± 2 Days), Visit 3 (Day 0), and Visit 5 (Day 7 ± 2 Days)</time_frame>
    <description>Symptom: Ocular discomfort pre and post CAE (ORA Scale)at 3 visits (Visits 1, 3, and 5)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Low Dose: DP 7.5 mA-min at 2.5 mA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 7.5 mA-min at 2.5 mA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose: DP 10.5 mA-min at 3.5 mA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 10.5 mA-min at 3.5 mA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: 10.5 mA-min at 3.5 mA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ocular Iontophoresis with Placebo (sodium citrate buffer solution 100 mM at 10.5 mA-min at 3.5 mA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGP-437 with EyeGate® II System</intervention_name>
    <description>Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System</description>
    <arm_group_label>Low Dose: DP 7.5 mA-min at 2.5 mA</arm_group_label>
    <arm_group_label>High Dose: DP 10.5 mA-min at 3.5 mA</arm_group_label>
    <other_name>Dexamethasone phosphate ophthalmic solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium citrate buffer solution with EyeGate® II System</intervention_name>
    <description>Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System</description>
    <arm_group_label>Placebo: 10.5 mA-min at 3.5 mA</arm_group_label>
    <other_name>Sodium citrate buffer solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a reported history of dry eye in each eye

          -  Be at least 12 years of age

          -  Demonstrate a response when exposed to the Controlled Adverse Environment model

        Exclusion Criteria:

          -  Have contraindications to the use of the test articles

          -  Have known allergy or sensitivity to the study medication or their components
             (including corticosteroids)

          -  Have any ocular infections, active ocular inflammation or preauricular lymphadenopathy

          -  Be current contact lens wearers or wear contacts during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ORA, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmic Research Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Research Associates</name>
      <address>
        <city>North Andover</city>
        <state>Massachusetts</state>
        <zip>01845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <disposition_first_submitted>August 20, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 25, 2010</disposition_first_posted>
  <last_update_submitted>August 27, 2010</last_update_submitted>
  <last_update_submitted_qc>August 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Stephen From/Chief Executive Officer</name_title>
    <organization>Eyegate Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>Iontophoresis</keyword>
  <keyword>Ophthalmic Delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

